The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, efficacy, and cost-effectiveness compared with reference drugs.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/biosimilars-retina-and-inflammatory-disease-get-ema-nod-2025a1000z3a?src=rss
Author :
Publish date : 2025-12-15 12:07:00
Copyright for syndicated content belongs to the linked Source.
